Contact Us
Drug Search Results
More Filters [+]

Dovitinib

Alternative Names: dovitinib, chir-258, tki258, tk1258, tk-1258, tk 1258
Latest Update: 2024-11-12
Latest Update Note: News Article

Product Description

Dovitinib is a pan-tyrosine kinase inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR) and other receptor tyrosine kinases (RTKs). Allarity exclusively in-licensed it (globally) from Novartis, who had completed a Phase 3 study in renal cell carcinoma (RCC) in addition to several promising Phase 2 studies in breast, liver and endometrial cancer and GIST. (Sourced from: https://allarity.com/pipeline/dovitinib/)

Mechanisms of Action: RTK Inhibitor,FGFR Inhibitor,VEGF Inhibitor,KITl Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dovitinib

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Diarrhea|Neutropenia|Thrombocytopenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
AL-2003

P1

Recruiting

Thrombocytopenia|Diarrhea|Neutropenia

2024-10-01

21%
AL-2003

P1

Recruiting

Thrombocytopenia|Diarrhea|Neutropenia

2024-10-01

21%

Recent News Events

Date

Type

Title

11/12/2024

News Article

 ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

11/12/2024

News Article

 ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

11/08/2024

News Article

 The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)

11/07/2024

News Article

 ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit

04/17/2024

PubMed

 Single-Cell Analysis of Rohon-Beard Neurons Implicates Fgf Signaling in Axon Maintenance and Cell Survival.

04/01/2024

PubMed

 TBX15 and SDHB expression changes in colorectal cancer serve as potential prognostic biomarkers.

12/26/2023

PubMed

 Identification of promising small-molecule inhibitors targeting STK17B for cancer therapeutics: molecular docking and molecular dynamics investigations.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions